T. Rowe Price Investment Management
CERE

T. Rowe Price Investment Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

T. Rowe Price Investment Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,824,387
Closed -$39.8M – 640
2023
Q3 		$39.8M Sell
1,824,387
-35,400
-2% -$886K 0.03% 395
2023
Q2 		$59.1M Sell
1,859,787
-141,781
-7% -$4.35M 0.04% 351
2023
Q1 		$48.8M Sell
2,001,568
-4,500
-0.2% -$132K 0.04% 372
2022
Q4 		$63.3M Buy
2,006,068
+4,631
+0.2% +$131K 0.05% 325
2022
Q3 		$56.6M Buy
+2,001,437
New +$59.6M 0.05% 332

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

T. Rowe Price Investment Management's CERE Position: Q4 2023 in Review

T. Rowe Price Investment Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q4 2023, closing a stake of 1,824,387 shares — an estimated $39.8M sold.

T. Rowe Price Investment Management first reported a position in CERE in Q3 2022 and held it in 5 quarters. The position peaked at $63.3M in Q4 2022. 195 funds tracked by Wall St. Rank hold CERE as of Q4 2023.

  • T. Rowe Price Investment Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 1,824,387 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q4 2023, an estimated $39.8M.
  • T. Rowe Price Investment Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2022 and held it in 5 quarters.
  • T. Rowe Price Investment Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $63.3M in Q4 2022.
  • 195 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q4 2023.

Based on T. Rowe Price Investment Management's 13F filing for Q4 2023, filed 14 Feb 2024.